We are dedicated to providing new solutions to the millions of patients suffering from chronic low back pain (CLBP). At any given time, low back pain impacts nearly 30% of the US population, leading to 52 million annual visits to hospitals, emergency departments, outpatient clinics, and physician offices.1 While the majority of patients with low back pain improve, up to 15% of these patients experience chronic low back pain.2

Today, patients with CLBP are treated with conservative treatments such as physical therapy or injections, medications such as opioids, or potentially surgical options including spinal fusion or total disc replacement. Based on two decades of scientific research, Relievant developed the Intracept Procedure — a minimally invasive procedure that targets the basivertebral nerve for the relief of chronic low back pain.* Intracept is supported with Level I clinical evidence, has 510(k) Clearance, and is commercially available in the United States.

“The Intracept Procedure is a new, minimally invasive option to treat chronic low back pain. The procedure is proven to be safe and effective in clinical trials, and is much less invasive than typical surgical options to treat chronic low back pain.”

Jeffrey Fischgrund, MD, Chairman, Department of Orthopedics, Beaumont Hospital, Royal Oak and principal investigator of the SMART Trial

1 Burden of Musculoskeletal Disease in the United States, Third Edition – Copyright © 2014–2015 by the United States Bone and Joint Initiative

2 Baker RM. Commentary on Classification of patients with incident non-specific low back pain: implications for research. The Spine Journal 16 (2016) 577–578

* Indications and Risks